Peak Bio, Inc.

Peak Bio, Inc., listed under ticker IGNY, is a clinical-stage biopharmaceutical company that entered the public markets through a business combination with Ignyte Acquisition Corp, a special purpose acquisition company focused on the healthcare and life sciences sector with an IPO in 2021. The company filed a Form 10-Q with the Securities and Exchange Commission on August 16, 2021, under accession number 0001206774-21-002187, reflecting its status as a post-combination reporting entity operating in the biotechnology industry. Peak Bio's pipeline centers on novel oncology therapeutics targeting cancer biology. Sign up on SpacDesk for full filing history, sponsor details, and deal analytics on IGNY and hundreds of other SPAC transactions.